Liste der Wissenschaftlichen Veröffentlichungen

  • 2018

    Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome.
    Heger LA, Kerber M, Hortmann M, Robinson S, Mauler M, Stallmann D, Duerschmied D, Bode C, Hehrlein C, Ahrens I.
    Acta Pharmacol Sin. 2018 Jul 10. doi: 10.1038/s41401-018-0055-1. [Epub ahead of print]

    Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction.
    Robinson S, Follo M, Haenel D, Mauler M, Stallmann D, Tewari M, Duerschmied D, Peter K, Bode C, Ahrens I, Hortmann M.
    Int J Cardiol. 2018 Apr 15;257:247-254. doi: 10.1016/j.ijcard.2017.10.111.

    Optimised care of elderly patients with acute coronary syndrome.
    Leonardi S, Bueno H, Ahrens I, Hassager C, Bonnefoy E, Lettino M.
    Eur Heart J Acute Cardiovasc Care. 2018 Apr;7(3):287-295. doi: 10.1177/2048872618761621. Epub 2018 Mar 5. No abstract available. 

    Coronary magnetic resonance imaging after routine implantation of bioresorbable vascular scaffolds allows non-invasive evaluation of vascular patency.
    von Zur Mühlen C, Reiss S, Krafft AJ, Besch L, Menza M, Zehender M, Heidt T, Maier A, Pfannebecker T, Zirlik A, Reinöhl J, Stachon P, Hilgendorf I, Wolf D, Diehl P, Wengenmayer T, Ahrens I, Bode C, Bock M.
    PLoS One. 2018 Jan 25;13(1):e0191413. doi: 10.1371/journal.pone.0191413. eCollection 2018.

  • 2017

    Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients.
    Robinson S, Follo M, Haenel D, Mauler M, Stallmann D, Heger LA, Helbing T, Duerschmied D, Peter K, Bode C, Ahrens I, Hortmann M.
    Acta Pharmacol Sin. 2017 Nov 30. doi: 10.1038/aps.2017.136.

    Circulating HtrA2 after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A potential novel biomarker for mitochondrial induced cardiomyocyte apoptosis and ischemia-reperfusion injury.
    Hortmann M, Robinson S, Mohr M, Haenel D, Mauler M, Laumann R, Stallmann D, Reinoehl J, Duerschmied D, Peter K, Bode C, Ahrens I. 
    Int J Cardiol. 2017 Dec 15;249:437. doi: 10.1016/j.ijcard.2017.08.022.

    Platelet-Targeted Delivery of Peripheral Blood Mononuclear Cells to the Ischemic Heart Restores Cardiac Function after Ischemia-Reperfusion Injury.
    Ziegler M, Wang X, Lim B, Leitner E, Klingberg F, Ching V, Yao Y, Huang D, Gao XM, Kiriazis H, Du XJ, Haigh JJ, Bobik A, Hagemeyer CE, Ahrens I, Peter K.
    Theranostics. 2017 Jul 22;7(13):3192-3206. doi: 10.7150/thno.19698.

    Circulating HtrA2 as a novel biomarker for mitochondrial induced cardiomyocyte apoptosis and ischemia-reperfusion injury in ST-segment elevation myocardial infarction.
    Hortmann M, Robinson S, Mohr M, Haenel D, Mauler M, Stallmann D, Reinoehl J, Duerschmied D, Peter K, Bode C, Ahrens I.
    Int J Cardiol. 2017 May 24. pii: S0167-5273(16)34126-2. doi: 10.1016/j.ijcard.2017.05.088.

    The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.
    Hortmann M, Robinson S, Mohr M, Mauler M, Stallmann D, Reinöhl J, Duerschmied D, Peter K, Carr J, Gibson CM, Bode C, Ahrens I.
    Eur Heart J Acute Cardiovasc Care. 2017 May 1:2048872617710789. doi: 10.1177/2048872617710789.

    Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation
    Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P.
    Dtsch Med Wochenschr. 2017 Jul;142(13):986-993. doi: 10.1055/s-0042-124132.

    Editor's Choice-The organization of chest pain units: Position statement of the Acute Cardiovascular Care Association.
    Claeys MJ, Ahrens I, Sinnaeve P, Diletti R, Rossini R, Goldstein P, Czerwińska K, Bueno H, Lettino M, Münzel T, Zeymer U.
    Eur Heart J Acute Cardiovasc Care. 2017 Apr;6(3):203-211. doi: 10.1177/2048872617695236.

    Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes.
    Staudacher DL, Putz V, Heger L, Reinöhl J, Hortmann M, Zelenkofske SL, Becker RC, Rusconi CP, Bode C, Ahrens I.
    Eur Heart J Acute Cardiovasc Care. 2017 Apr 1:2048872617703065. doi: 10.1177/2048872617703065.

    Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM.
    Eur Heart J Cardiovasc Pharmacother. 2017 Feb 15. doi: 10.1093/ehjcvp/pvw044.

  • 2016

    Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation.
    Staudacher DL, Biever PM, Benk C, Ahrens I, Bode C, Wengenmayer T.
    PLoS One. 2016 Jul 28;11(7):e0159973. doi: 10.1371/journal.pone.0159973.

    Dual pathway therapy in acute coronary syndrome.
    Stachon P, Ahrens I, Bode C, Zirlik A.
    J Thromb Thrombolysis. 2016 Aug;42(2):254-60. doi: 10.1007/s11239-015-1306-3.

    Platelet-neutrophil complex formation-a detailed in vitro analysis of murine and human blood samples.
    Mauler M, Seyfert J, Haenel D, Seeba H, Guenther J, Stallmann D, Schoenichen C, Hilgendorf I, Bode C, Ahrens I, Duerschmied D.
    J Leukoc Biol. 2016 May;99(5):781-9. doi: 10.1189/jlb.3TA0315-082R. Epub 2015 Nov 17.

    Preprocedural planning and implantation of a transcatheter aortic valve without the use of contrast agent.
    Reinöhl J, Pache G, Ahrens I, Heidt T, Psyrakis D, Latib A, De Marco F, Schröfel H, Beyersdorf F, Zehender M, Bode C, von Zur Mühlen C.
    EuroIntervention. 2016 Mar;11(12):1433. doi: 10.4244/EIJY15M07_06.

    Aortic root volume is associated with contained rupture of the aortic annulus in balloon-expandable transcatheter aortic valve replacement.
    Reinöhl J, Psyrakis D, Kaier K, Kodirov S, Siepe M, Gutmann A, von zur Mühlen C, Moser M, Ahrens I, Pache G, Zirlik A, Langer M, Beyersdorf F, Zehender M, Bode C, Blanke P.
    Catheter Cardiovasc Interv. 2016 Mar;87(4):807-17. doi: 10.1002/ccd.26260.

  • 2015

    Asymptomatic atrial fibrillation and risk of stroke.
    Stachon P, Ahrens I, Faber T, Bode C, Zirlik A.
    Panminerva Med. 2015 Dec;57(4):211-5. Epub 2016 Jan 12. Review.

    HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi.
    Ahrens I, Chen YC, Topcic D, Bode M, Haenel D, Hagemeyer CE, Seeba H, Duerschmied D, Bassler N, Jandeleit-Dahm KA, Sweet MJ, Agrotis A, Bobik A, Peter K.
    Thromb Haemost. 2015 Nov;114(5):994-1003. doi: 10.1160/TH14-12-1073. Epub 2015 Jul 23.

    Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry.
    Staudacher DL, Kaiser M, Hehrlein C, Bode C, Ahrens I.
    PLoS One. 2015 Oct 6;10(10):e0140101. doi: 10.1371/journal.pone.0140101.

    Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System.
    Gutmann A, Kaier K, Sorg S, von Zur Mühlen C, Siepe M, Moser M, Geibel A, Zirlik A, Ahrens I, Baumbach H, Beyersdorf F, Vach W, Zehender M, Bode C, Reinöhl J.
    Int J Cardiol. 2015 Jan 20;179:231-7. doi: 10.1016/j.ijcard.2014.11.095. Epub 2014 Nov 11.

  • 2012

    Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I, Bode C.
    Future Cardiol. 2012 Jul;8(4):533-41.

    Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
    Ahrens I, Bode C.
    Hämostaseologie. 2012 Jul 12;32(3).

    Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.
    Ahrens I, Peter K, Lip GY, Bode C.
    Discov Med. 2012 Jun;13(73):445-50.

    Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.
    Ahrens I, Peter K, Lip GY, Bode C.
    Discov Med. 2012 Jun;13(73):433-43.

    Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice.
    Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I.
    Circulation. 2012 Jun 26;125(25):3117-26.

    New Parenteral Anticoagulants: Focus on Factor Xa and Thrombin Inhibitors.
    Ahrens I, Bode C.
    Curr Drug Discov Technol. 2012 Jun 1;9(2):129-36.

    Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
    Duerschmied D, Ahrens I, Mauler M, Brandt C, Weidner S, Bode C, Moser M.
    PLoS One. 2012;7(2):e32656. Epub 2012 Feb 27.

  • 2011

    Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early EPCs reveals highly differential gene expression.
    Ahrens I, Domeij H, Topcic D, Haviv I, Merivirta R-M, Agrotis A, Leitner E, Jowett JB, Bode C, Lappas M, Peter K. 
    PLoS One. 2011;6(8):e23210.

    Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC.
    Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch J-P, Bode C, Schmidt HHHW, Peter K.
    Atherosclerosis. 2011 Oct;218(2):431-4.

    Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells.
    Ahrens I, Domeij H, Eisenhardt SU, Topcic D, Albrecht M, Leitner E, Viitaniemi K, Jowett JB, Lappas M, Bode C, Haviv I, Peter K. 
    Basic Res Cardiol. 2011 Sep;106(5):879-95.

    GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors.
    Hu H, Armstrong PC, Khalil E, Chen YC, Straub A, Li M, Soosairajah J, Hagemeyer CE, Bassler N, Huang D, Ahrens I, Krippner G, Gardiner E, Peter K.
    PLoS One. 2011 Apr 28;6(4):e19190.

    What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Ahrens I, Lip GY, Peter K.
    Thromb Haemost. 2011 Apr;105(4):574-8.

    High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice.
    Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, Takahashi HK, Liu K, Peter K, Nishibori M, Bobik A.
    Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):313-9

  • 2010

    New oral anticoagulant drugs in cardiovascular disease.
    Ahrens I, Lip GY, Peter K.
    Thromb Haemost. 2010 Jul 5;104(1):49-60

    Genetic transfer of fusion proteins effectively inhibits VCAM-1-mediated cell adhesion and transmigration via inhibition of cytoskeletal anchorage.
    Hagemeyer CE*, Ahrens I*, Bassler N, Dschachutaschwili N, Chen YC, Eisenhardt SU, Bode C, Peter K. *these authors contributed equally
    J Cell Mol Med. 2010 Jan;14(1-2):290-302.'

  • 2009

    Novel antiplatelet therapies following percutaneous coronary interventions.
    Ahrens I, Bode C.
    Curr Opin Investig Drugs. 2009 Sep;10(9):902-11.

    Novel antiplatelet therapies following percutaneous coronary interventions.
    Ahrens I, Bode C.
    Curr Opin Investig Drugs. 2009 Sep;10(9):902-11.

    Novel antiplatelet therapies following percutaneous coronary interventions.
    Ahrens I, Bode C.
    Curr Opin Investig Drugs. 2009 Sep;10(9):902-11.

  • 2008

    Selenium supplementation induces metalloproteinase-dependent L-selectin shedding from monocytes.
    Ahrens I, Ellwanger C, Smith BK, Bassler N, Chen YC, Neudorfer I, Ludwig A, Bode C, Peter K.
    J Leukoc Biol. 2008 Jun;83(6):1388-95

    Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths.
    von Zur Muhlen C, von Elverfeldt D, Choudhury RP, Ender J, Ahrens I, Schwarz M, Hennig J, Bode C, Peter K.
    Mol Imaging. 2008 Mar-Apr;7(2):59-67.

    Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies.
    Ahrens I, Peter K.
    Thromb Haemost. 2008 May;99(5):803-4

    Humanizing mouse thrombi.
    Ahrens I, Peter K.
    Nat Biotechnol. 2008 Jan;26(1):62-3.

  • 2007

    Factor Xa-inhibition in interventional cardiology
    Ahrens I, Peter K, Bode C.
    Hamostaseologie. 2007 Dec;27(5):328-32.

    Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
    Ahrens I, Smith BK, Bode C, Peter K.
    Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):609-20.

    CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.
    Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schönbeck U, Bode C, Libby P, Peter K.
    Circulation, 2007 Mar 27;115(12):1571-80

    Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
    Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K.
    Arterioscler Thromb Vasc Biol. 2007 May;27(5):1206-12

    A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
    Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, Peter K.
    Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):e9-15.

    Tiefe Beinvenenthrombosen. Diagnose und Therapie (CME Artikel)
    Ahrens I, Bode C.
    Internistische Praxis 47, 59-71 (2007)

    Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers.
    Ahrens I, Schwarz M, Peter K, Bode C.
    Transfusion Medicine and Hemotherapy 2007;34 (1): 44-54

  • 2006

    A novel functional role for the highly conserved alpha-subunit KVGFFKR motif distinct from integrin alphaIIbbeta3 activation processes. 
    Aylward K, Meade G, Ahrens I, Devocelle M, Moran N.
    J Thromb Haemost. 2006 Aug;4(8):1804-12

    Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
    Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K.
    Circ Res. 2006 Jul 7;99(1):25-33

    Therapy of acute myocardial infarction: COMMIT (Clopidogrel and Metoprolol Infarction Trial)
    Ahrens I, Bode C.
    Internist (Berl). 2006 Jul;47(7):764-6.

    Inhibition of platelet aggregation for the secondary prevention after ACS: when clopidogrel instead of ASA, when clopidogrel and ASA?
    Klaus T, Ahrens I, Bode C.
    Hämostaseologie. 2006 Jan;26(1):55-8.

    Evidence for a differential functional regulation of the two β3-integrins αVβ3 and αIIbβ3. 
    Ahrens, IG; Moran N; Aylward K; Meade G; Moser M; Assefa D, Fitzgerald DJ; Bode C; Peter K. Experimental Cell Research, 2006 Apr 1;312(6):925-37

  • 2005

    Inhibition of Platelet Activation and Aggregation
    Ahrens I, Bode C, Peter K.
    Handb Exp Pharmacol. 2005;(170):443-62

    Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?
    Ahrens I, Bode C
    Herz. 2005 May;30(3)

  • 2004

    Distinct Roles of Ligand Affinity and Cytoskeletal Anchorage in IIb3 (GP IIb/IIIa)-Mediated Cell Aggregation and Adhesion 
    Peter K, Ahrens I, Schwarz M, Bode C, Ylänne J. 
    Platelets. 2004 Nov;15(7):427-38.

  • 2003

    Use of GPIIb/IIIa inhibitors in cardiovascular medicine 
    Ahrens I, Peter K & Bode C
    Expert Rev. Cardiovascular Ther. 1(2), 233–242 (2003)

    Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaM beta2) and can be inhibited by semiconductor coating.
    Schuler P, Assefa D, Ylanne J, Basler N, Olschewski M, Ahrens I, Nordt T, Bode C, Peter K.
    Cell Commun Adhes. 2003 Jan-Feb;10(1):17-26

  • 2002

    Glykoprotein-IIb/IIIa-Antagonisten - Ist eine Differentialtherapie denkbar ?
    Ahrens I, Peter K, Bode C.
    Arzneimitteltherapie 2002;20:82-87